Welcome, Guest. Please login or register.
November 27, 2020, 09:58:27 pm

Login with username, password and session length

  • Total Members: 6249
  • Latest: Sugar67
  • Total Posts: 55050
  • Total Topics: 4814
  • Online Today: 69
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 42
Total: 42


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: When Will We See Drug Treatments for NASH Fibrosis?  (Read 1172 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 770
    • Hep Mag
When Will We See Drug Treatments for NASH Fibrosis?
« on: October 02, 2019, 10:58:04 am »
Perhaps as many as one in four people in North America have non-alcoholic fatty liver disease (NAFLD), in which excess fat accumulates in the liver of an individual who drinks little or no alcohol. The disease is tightly linked with metabolic syndrome and insulin resistance and is a top driver of liver disease, including non-alcoholic steatohepatitis (NASH).

NAFLD and NASH often occur with fibrosis (scarring) of the liver, and yet to date no medications have been approved to treat such liver damage in this population. For anyone with NAFLD and fibrosis, the primary recommended treatment is moderate intensity exercise along with a healthy diet to promote weight loss.



© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.